Fesoterodine
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
| [2-[(1R)-3-(Di(propan-2-yl)amino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate | |
| Identifiers | |
| CAS number | 286930-03-8 |
| ATC code | G04BD11 |
| PubChem | 6918558 |
| Chemical data | |
| Formula | C26H37NO3 |
| Mol. mass | 411.278 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 52% (active metabolite) |
| Protein binding | 50% (active metabolite) |
| Metabolism | Hepatic (CYP2D6- and 3A4-mediated) |
| Half life | 7–8 hours (active metabolite) |
| Excretion | Renal (70%) and fecal (7%) |
| Therapeutic considerations | |
| Licence data | |
| Pregnancy cat. |
C(US) |
| Legal status |
℞ Prescription only |
| Routes | Oral
|
Fesoterodine (INN, brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome.[1] It was approved by the European Medicines Agency in April 2007[2] and was approved by the US Food and Drug Administration on October 31, 2008.[3]
Fesoterodine is a prodrug. It is broken down into its active metabolite, 5-hydroxymethyl tolterodine, by plasma esterases.
[edit] References
- ^ "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006. http://www.medicalnewstoday.com/articles/41688.php.
- ^ "Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008. http://www.emea.europa.eu/humandocs/Humans/EPAR/toviaz/toviaz.htm.
- ^ Pfizer Inc. (2008-10-31). "Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder". Press release. http://www.drugs.com/newdrugs/pfizer-s-toviaz-fesoterodine-fumarate-receives-fda-approval-overactive-bladder-1167.html. Retrieved 2008-11-06.
|
|||||||||||||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
